This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Inotek Pharmaceuticals Corporation. Active years: 2013-2016.
Company Filing History:
Years Active: 2013-2016
Title: Inventor Rudolf A. Baumgartner - Innovating Eye Care
Introduction
Rudolf A. Baumgartner is an accomplished inventor based in Sudbury, MA, significantly impacting the field of ophthalmology with his innovative contributions. With a total of three patents to his name, he has devoted his expertise to developing solutions aimed at improving eye health, particularly in the area of intraocular pressure management.
Latest Patents
His most recent patents focus on the "Combination, kit and method of reducing intraocular pressure." These patents detail a composition or kit that comprises a combination of a prostaglandin analog and an adenosine receptor A agonist, directed towards effectively managing intraocular pressure (IOP) in individuals. One embodiment features latanoprost as the prostaglandin analog, combined with Compound A, which has a defined chemical structure aimed at ensuring optimal therapeutic outcomes.
Career Highlights
Rudolf A. Baumgartner's career highlights include his ongoing work with Inotek Pharmaceuticals Corporation, where he continues to explore and develop innovative treatments for eye diseases. His dedication to research and development has positioned him as a key player in his field, contributing to advancements that enhance patient care and treatment efficacy.
Collaborations
Throughout his career, Baumgartner has collaborated with notable colleagues, including Norman N. Kim and William K. McVicar. These partnerships in research and development have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation within the company.
Conclusion
Rudolf A. Baumgartner's innovative patents and collaborative efforts exemplify his commitment to advancing eye care solutions. As an inventor, he continues to pave the way for future developments in managing intraocular pressure, ultimately contributing to improved patient outcomes in ophthalmology.